Ind-Swift Ltd
Incorporated in 1986, Ind-Swift Ltd deals in manufacturing and exporting of pharmaceutical products
- Market Cap ₹ 89.4 Cr.
- Current Price ₹ 16.6
- High / Low ₹ 34.7 / 12.0
- Stock P/E 11.4
- Book Value ₹ -74.3
- Dividend Yield 0.00 %
- ROCE 11.9 %
- ROE %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 18.2% CAGR over last 5 years
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 9.35% over past five years.
- Contingent liabilities of Rs.72.4 Cr.
- Earnings include an other income of Rs.328 Cr.
- Working capital days have increased from -13.2 days to 64.5 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
570 | 417 | 308 | 263 | 270 | 289 | 330 | 356 | 398 | 411 | 502 | 515 | |
602 | 487 | 465 | 328 | 262 | 278 | 306 | 315 | 352 | 369 | 448 | 492 | |
Operating Profit | -32 | -70 | -157 | -65 | 8 | 11 | 23 | 41 | 45 | 42 | 54 | 23 |
OPM % | -6% | -17% | -51% | -25% | 3% | 4% | 7% | 12% | 11% | 10% | 11% | 4% |
11 | 2 | 13 | -246 | -20 | 34 | 22 | 14 | 24 | 72 | 53 | 328 | |
Interest | 77 | 40 | 19 | 16 | 7 | 3 | 29 | 52 | 57 | 60 | 63 | 39 |
Depreciation | 26 | 39 | 36 | 36 | 35 | 34 | 34 | 33 | 32 | 29 | 27 | 24 |
Profit before tax | -124 | -147 | -200 | -363 | -53 | 8 | -17 | -29 | -20 | 26 | 16 | 288 |
Tax % | -7% | -2% | 0% | 0% | 1% | 0% | 15% | 1% | 2% | 0% | 14% | 2% |
-116 | -145 | -200 | -364 | -54 | 8 | -19 | -30 | -20 | 26 | 14 | 283 | |
EPS in Rs | -22.95 | -28.83 | -39.71 | -67.25 | -9.99 | 1.51 | -3.53 | -5.51 | -3.70 | 4.81 | 2.63 | 52.33 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | 9% |
3 Years: | 9% |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 18% |
3 Years: | 33% |
TTM: | 132% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | 39% |
3 Years: | 15% |
1 Year: | -23% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
Reserves | 84 | -64 | -264 | -636 | -690 | -688 | -724 | -706 | -731 | -716 | -702 | -413 |
1,024 | 1,054 | 1,061 | 1,062 | 1,055 | 1,010 | 1,017 | 1,023 | 1,036 | 993 | 1,014 | 874 | |
272 | 228 | 254 | 232 | 237 | 265 | 298 | 344 | 316 | 361 | 331 | 257 | |
Total Liabilities | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 632 | 649 | 654 | 728 |
440 | 404 | 374 | 342 | 311 | 291 | 270 | 244 | 236 | 216 | 184 | 243 | |
CWIP | 4 | 4 | 4 | 2 | 0 | 0 | 0 | 13 | 9 | 30 | 51 | 0 |
Investments | 45 | 45 | 45 | 44 | 44 | 41 | 24 | 70 | 64 | 54 | 1 | 6 |
900 | 775 | 638 | 281 | 258 | 267 | 308 | 344 | 323 | 349 | 418 | 480 | |
Total Assets | 1,390 | 1,228 | 1,061 | 669 | 613 | 598 | 602 | 672 | 632 | 649 | 654 | 728 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
103 | 86 | -106 | 7 | 1 | 43 | 35 | 83 | 50 | 73 | 15 | 16 | |
-14 | -6 | -4 | -4 | -3 | -14 | -11 | -17 | -18 | -29 | 77 | 3 | |
-89 | -81 | 110 | -11 | -4 | -13 | -26 | -54 | -45 | -47 | -42 | -13 | |
Net Cash Flow | 0 | -1 | 0 | -8 | -5 | 16 | -3 | 12 | -13 | -3 | 50 | 6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 282 | 425 | 451 | 151 | 113 | 95 | 104 | 111 | 83 | 93 | 111 | 112 |
Inventory Days | 202 | 117 | 151 | 86 | 108 | 112 | 102 | 123 | 120 | 150 | 83 | 150 |
Days Payable | 152 | 155 | 290 | 356 | 426 | 454 | 440 | 454 | 353 | 393 | 262 | 143 |
Cash Conversion Cycle | 331 | 387 | 311 | -119 | -206 | -246 | -234 | -220 | -149 | -150 | -68 | 120 |
Working Capital Days | 317 | 325 | 409 | -37 | -57 | -99 | -79 | -94 | -69 | -77 | -27 | 64 |
ROCE % | -4% | -10% | -20% | -14% | -4% | -4% | 2% | 8% | 11% | 8% | 13% | 12% |
Documents
Announcements
- Closure of Trading Window 1d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
27 Jun - Newspaper Publication of the financial Results for the Quarter and Year Ended 31.03.2025
- Standalone And Consolidated Audited Financial Results For The Quarter And Financial Year Ended March 31, 2025 25 Jun
-
Board Meeting Outcome for Standalone And Consolidated Audited Financial Results For Quarter And Financial Year Ended March 31, 2025
25 Jun - Ind Swift Ltd reports audited FY25 standalone and consolidated results with Rs.287.9 Cr profit and pending NCLT amalgamation.
-
Intimation To Furnish Valid PAN, KYC Details And Nomination By Shareholders Holding Physical Shares
21 Jun - SEBI mandates physical shareholders to update PAN, KYC, nomination details for continued services.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Company has expertise in finished goods dosage, Active Pharmaceutical Ingredients (API’s) and herbal products. Company also diversified into multiple fields viz., Infrastructure, Printing, Packaging & Stationary, Education, and Media Publication with its every unit as an independent profit earning center